TFEB is overexpressed in TFEB-rearranged renal cell carcinomas as well as in renal tumors with amplifications of TFEB at 6p21.1. As recent literature suggests that renal tumors with 6p21.1 amplification behave more aggressively than those with rearrangements of TFEB, we compared relative TFEB gene expression in these tumors. This study included 37 TFEB-altered tumors: 15 6p21.1-amplified and 22 TFEB-rearranged (including 5 cases from The Cancer Genome Atlas data set). TFEB status was verified using a combination of fluorescent in situ hybridization (n=27) or comprehensive molecular profiling (n=13) and digital droplet polymerase chain reaction was used to quantify TFEB mRNA expression in 6p21.1-amplified (n=9) and TFEB-rearranged renal tumors (n=19). These results were correlated with TFEB immunohistochemistry. TFEB-altered tumors had higher TFEB expression when normalized to B2M (mean: 168.9%, n=28), compared with non-TFEB-altered controls (mean: 7%, n=18, P=0.005). Interestingly, TFEB expression in tumors with rearrangements (mean: 224.7%, n=19) was higher compared with 6p21.1-amplified tumors (mean: 51.2%, n=9; P=0.06). Of note, classic biphasic morphology was only seen in TFEB-rearranged tumors and when present correlated with 6.8-fold higher TFEB expression (P=0.00004). Our results suggest that 6p21.1 amplified renal tumors show increased TFEB gene expression but not as much as t(6;11) renal tumors. These findings correlate with the less consistent/diffuse expression of downstream markers of TFEB activation (cathepsin K, melan A, HMB45) seen in the amplified neoplasms. This suggests that the aggressive biological behavior of 6p21.1 amplified renal tumors might be secondary to other genes at the 6p21.1 locus that are co-amplified, such as VEGFA and CCND3, or other genetic alterations.

Department of Pathology and Laboratory Medicine Henry Ford Health System Detroit

Department of Pathology The Johns Hopkins Medical Institutions Baltimore MD

Department of Pathology University Hospital Plzeň Charles University Pilsen Czech Republic

Department of Pathology University of Michigan Health System Ann Arbor MI

Departments of Pathology

Human Oncology and Pathogenesis Program Memorial Sloan Kettering Cancer Center New York NY

Surgery Urology Service

Zobrazit více v PubMed

Argani P, Hawkins A, Griffin CA, et al. A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11)(p21.1;q12) chromosome translocation. Am J Pathol. 2001;158:2089–2096. PubMed PMC

Argani P, Reuter VE, Zhang L, et al. TFEB-amplified renal cell carcinomas: an aggressive molecular subset demonstrating variable melanocytic marker expression and morphologic heterogeneity. Am J Surg Pathol. 2016;40:1484–1495. PubMed PMC

Dijkhuizen T, Berg EV, Störkel S, et al. Two cases of renal cell carcinoma, clear cell type, revealing a t(6;11)(p21;q13). Cancer Genetics; 1996:141.

van Asseldonk M, Schepens M, de Bruijn D, et al. Construction of a 350-kb sequence-ready 11q13 cosmid contig encompassing the markers D11S4933 and D11S546: mapping of 11 genes and 3 tumor-associated translocation breakpoints. Genomics. 2000;66:35–42. PubMed

Kuiper RP, Schepens M, Thijssen J, et al. Upregulation of the transcription factor TFEB in t(6;11)(p21;q13)-positive renal cell carcinomas due to promoter substitution. Hum Mol Genet. 2003;12:1661–1669. PubMed

Peckova K, Vanecek T, Martinek P, et al. Aggressive and nonaggressive translocation t(6;11) renal cell carcinoma: comparative study of 6 cases and review of the literature. Ann Diagn Pathol. 2014;18:351–357. PubMed

Durinck S, Stawiski EW, Pavia-Jimenez A, et al. Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. Nat Genet. 2015;47:13–21. PubMed PMC

Williamson SR, Grignon DJ, Cheng L, et al. Renal cell carcinoma with chromosome 6p amplification including the TFEB gene: a novel mechanism of tumor pathogenesis? Am J Surg Pathol. 2017;41:287–298. PubMed

Gupta S, Johnson SH, Vasmatzis G, et al. TFEB-VEGFA (6p21.1) co-amplified renal cell carcinoma: a distinct entity with potential implications for clinical management. Mod Pathol. 2017;30:998–1012. PubMed

Skala SL, Xiao H, Udager AM, et al. Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays. Mod Pathol. 2018;31:179–197. PubMed

Calio A, Brunelli M, Segala D, et al. VEGFA amplification/increased gene copy number and VEGFA mRNA expression in renal cell carcinoma with TFEB gene alterations. Mod Pathol. 2018. PubMed

Mendel L, Ambrosetti D, Bodokh Y, et al. Comprehensive study of three novel cases of TFEB-amplified renal cell carcinoma and review of the literature: Evidence for a specific entity with poor outcome. Genes Chromosomes Cancer. 2018;57:99–113. PubMed

Calio A, Brunelli M, Segala D, et al. t(6;11) renal cell carcinoma: a study of seven cases including two with aggressive behavior, and utility of CD68 (PG-M1) in the differential diagnosis with pure epithelioid PEComa/epithelioid angiomyolipoma. Mod Pathol. 2018;31:474–487. PubMed

Malouf GG, Su X, Yao H, et al. Next-generation sequencing of translocation renal cell carcinoma reveals novel RNA splicing partners and frequent mutations of chromatin-remodeling genes. Clin Cancer Res. 2014;20:4129–4140. PubMed PMC

Cancer Genome Atlas Research N, Linehan WM, Spellman PT, et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med. 2016;374:135–145. PubMed PMC

Cheng DT, Mitchell TN, Zehir A, et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn. 2015;17:251–264. PubMed PMC

Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23:703–713. PubMed PMC

Smith NE, Illei PB, Allaf M, et al. t(6;11) renal cell carcinoma (RCC): expanded immunohistochemical profile emphasizing novel RCC markers and report of 10 new genetically confirmed cases. Am J Surg Pathol. 2014;38:604–614. PubMed PMC

Argani P, Yonescu R, Morsberger L, et al. Molecular confirmation of t(6;11)(p21;q12) renal cell carcinoma in archival paraffin-embedded material using a break-apart TFEB FISH assay expands its clinicopathologic spectrum. Am J Surg Pathol. 2012;36:1516–1526. PubMed PMC

Ross DS, Zehir A, Cheng DT, et al. Next-generation assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) amplification status: clinical validation in the context of a hybrid capture-based, comprehensive solid tumor genomic profiling assay. J Mol Diagn. 2017;19:244–254. PubMed PMC

Gupta S, Vanderbilt CM, Cotzia P, et al. JAK2, PD-L1, and PD-L2 (9p24.1) amplification in metastatic mucosal and cutaneous melanomas with durable response to immunotherapy. Hum Pathol. 2018. PubMed PMC

Gupta S, Vanderbilt CM, Cotzia P, et al. Next-generation sequencing-based assessment of JAK2, PD-L1, and PD-L2 copy number alterations at 9p24.1 in breast cancer: potential implications for clinical management. J Mol Diagn. 2018. PubMed PMC

Zhu G, Benayed R, Ho C, et al. Diagnosis of known sarcoma fusions and novel fusion partners by targeted RNA sequencing with identification of a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma. Mod Pathol. 2018. PubMed PMC

Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1. PubMed PMC

Pecciarini L, Cangi MG, Lo Cunsolo C, et al. Characterization of t(6;11)(p21;q12) in a renal-cell carcinoma of an adult patient. Genes Chromosomes Cancer. 2007;46:419–426. PubMed

Camparo P, Vasiliu V, Molinie V, et al. Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature. Am J Surg Pathol. 2008;32:656–670. PubMed

Ishihara A, Yamashita Y, Takamori H, et al. Renal carcinoma with (6;11)(p21;q12) translocation: report of an adult case. Pathol Int. 2011;61:539–545. PubMed

Inamura K, Fujiwara M, Togashi Y, et al. Diverse fusion patterns and heterogeneous clinicopathologic features of renal cell carcinoma with t(6;11) translocation. Am J Surg Pathol. 2012;36:35–42. PubMed

Hora M, Urge T, Travnicek I, et al. MiT translocation renal cell carcinomas: two subgroups of tumours with translocations involving 6p21 [t (6; 11)] and Xp11.2 [t (X;1 or X or 17)]. Springerplus. 2014;3:245. PubMed PMC

Lilleby W, Vlatkovic L, Meza-Zepeda LA, et al. Translocational renal cell carcinoma (t(6;11)(p21;q12) with transcription factor EB (TFEB) amplification and an integrated precision approach: a case report. J Med Case Rep. 2015;9:281. PubMed PMC

Kojima F, Kuroda N, Matsuzaki I, et al. Aggressive TFEB-rearranged renal cell carcinoma mimicking chromophobe and clear cell renal cell carcinoma. Pathol Int. 2019. PubMed

Davis IJ, Hsi BL, Arroyo JD, et al. Cloning of an Alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation. Proc Natl Acad Sci U S A. 2003;100:6051–6056. PubMed PMC

Argani P, Lae M, Hutchinson B, et al. Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. Am J Surg Pathol. 2005;29:230–240. PubMed

Argani P, Lae M, Ballard ET, et al. Translocation carcinomas of the kidney after chemotherapy in childhood. J Clin Oncol. 2006;24:1529–1534. PubMed

Hora M, Hes O, Urge T, et al. A distinctive translocation carcinoma of the kidney [“rosette-like forming,” t(6;11), HMB45-positive renal tumor]. Int Urol Nephrol. 2009;41:553–557. PubMed

Zhan HQ, Wang CF, Zhu XZ, et al. Renal cell carcinoma with t(6;11) translocation: a patient case with a novel Alpha-TFEB fusion point. J Clin Oncol. 2010;28:e709–713. PubMed

Zhong M, De Angelo P, Osborne L, et al. Translocation renal cell carcinomas in adults: a single-institution experience. Am J Surg Pathol. 2012;36:654–662. PubMed PMC

Rao Q, Liu B, Cheng L, et al. Renal cell carcinomas with t(6;11)(p21;q12): A clinicopathologic study emphasizing unusual morphology, novel alpha-TFEB gene fusion point, immunobiomarkers, and ultrastructural features, as well as detection of the gene fusion by fluorescence in situ hybridization. Am J Surg Pathol. 2012;36:1327–1338. PubMed

Rao Q, Zhang XM, Tu P, et al. Renal cell carcinomas with t(6;11)(p21;q12) presenting with tubulocystic renal cell carcinoma-like features. Int J Clin Exp Pathol. 2013;6:1452–1457. PubMed PMC

Matsuura K, Inoue T, Kai T, et al. Molecular analysis of a case of renal cell carcinoma with t(6;11)(p21;q12) reveals a link to a lysosome-like structure. Histopathology. 2014;64:306–309. PubMed

Chaste D, Vian E, Verhoest G, et al. Translocation renal cell carcinoma t(6;11)(p21;q12) and sickle cell anemia: first report and review of the literature. Korean J Urol. 2014;55:145–147. PubMed PMC

Falzarano SM, McKenney JK, Montironi R, et al. Renal cell carcinoma occurring in patients with prior neuroblastoma: a heterogenous group of neoplasms. Am J Surg Pathol. 2016;40:989–997. PubMed

Saleeb RM, Srigley JR, Sweet J, et al. Melanotic MiT family translocation neoplasms: expanding the clinical and molecular spectrum of this unique entity of tumors. Pathol Res Pract. 2017;213:1412–1418. PubMed

Williamson SR, Eble JN, Palanisamy N. Sclerosing TFEB-rearrangement renal cell carcinoma: a recurring histologic pattern. Hum Pathol. 2017;62:175–179. PubMed

Suarez-Vilela D, Izquierdo-Garcia F, Mendez-Alvarez JR, et al. Renal translocation carcinoma with expression of TFEB: presentation of a case with distinctive histological and immunohistochemical features. Int J Surg Pathol. 2011;19:506–509. PubMed

Cajaiba MM, Dyer LM, Geller JI, et al. The classification of pediatric and young adult renal cell carcinomas registered on the children’s oncology group (COG) protocol AREN03B2 after focused genetic testing. Cancer. 2018;124:3381–3389. PubMed PMC

Wyvekens N, Rechsteiner M, Fritz C, et al. Histological and molecular characterization of TFEB-rearranged renal cell carcinomas (In Press). Virchows Arch. 2019. PubMed

Martin EE, Mehra R, Jackson-Cook C, et al. Renal cell carcinoma with TFEB translocation versus unclassified renal cell carcinoma with TFEB amplification. 2017;22:305–312.

Kuroda N, Yorita K, Sasaki N, et al. Clinicopathological study of 5 cases of renal cell carcinoma with t(6;11)(p21;q12). Pol J Pathol. 2017;68:66–72. PubMed

Petersson F, Vanecek T, Michal M, et al. A distinctive translocation carcinoma of the kidney; “rosette forming,” t(6;11), HMB45-positive renal tumor: a histomorphologic, immunohistochemical, ultrastructural, and molecular genetic study of 4 cases. Hum Pathol. 2012;43:726–736. PubMed

Qu X, Tretiakova MS, Chen Y, et al. TFEB amplification renal cell carcinoma detected by chromosome genomic array testing: a case report for diagnosis of a novel entity. Journal of Clinical and Molecular Pathology. 2017;1:7 Available from: iMedPub, Hyderabad, India. Accessed March12, 2019.

Andeen NK, Qu X, Antic T, et al. Clinical utility of chromosome genomic array testing for unclassified and advanced-stage renal cell carcinomas. Arch Pathol Lab Med. 2018. PubMed

Mayoral Guisado C, Gómez Durán Á, Agustín Benítez López D, et al. [TFEB-amplified renal cell carcinoma. A case report and review of the literature]. Rev Esp Patol. 2018;51:248–252. PubMed

New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia

Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers: III: Molecular Pathology of Kidney Cancer

Molecular Genetics of Renal Cell Tumors: A Practical Diagnostic Approach